Vimpat (lacosamide, from UCB), an antiepileptic drug (AED), will be available the first week of June 2009. Vimpat tablets are indicated as adjunctive therapy for the treatment of partial-onset seizures in patients ≥17 years of age with epilepsy. Vimpat injection is indicated as short-term replacement when oral administration is not feasible in these patients.
Vimpat is a C-V controlled substance. It will be available in 50mg, 100mg, 150mg, and 200mg tablet dosage strengths, as well as an IV infusion. The formulations can be used interchangeably at equivalent dosing.
For more information call (800) 477-7877 or visit www.Vimpat.com.